UCLA Jonsson Comprehensive Cancer Center
@UCLAHealthJCCC
Official account for the UCLA Jonsson Comprehensive Cancer Center, a leader in cancer care, research and education.
Congratulations to Travis Courtney, @JesusJ_MD, @_eulanca (outstanding PGY-5 Radiation Oncology Residents!) and @UCLAHealthJCCC Head & Neck Cancer Program for our recent paper showing the added value of a post-op FDG PET/CT scan! academic.oup.com/jncics/advance…
Colorectal cancer is one of the most preventable cancers, yet Black Americans continue to face the highest burden. A new @NatRevGastroHep review co-led by @drfolamay outlines the actions needed to close the gap. Read more: bit.ly/454sDm8
In this @OncLive video series, UCLA’s @MarlaLipsycMD discusses the role of ctDNA in breast cancer surveillance and what it could mean for patient care. Watch the episodes here: bit.ly/3TT071J
So great to see this labor of love published! In this month's @NatRevGastroHep, @samirguptaGI, @AhJemal, @wmehtsun and I examine Black–White #disparities across the #CRC continuum in the US--from risk factors to screening, incidence, mortality, survival, treatment, and solutions.…
Dr. Sanaz Memarzadeh (@golabnow) is leading a cross-disciplinary research force at UCLA to change the trajectory of ovarian cancer. Her mission: eliminate relapse and engineer hope for women with one of the deadliest cancers. Read more about her work: bit.ly/4nNp5xb

Check out our recent review article on ADCs in breast cancer! Grateful for the mentorship and guidance of @dradityabardia and Dr. John Glaspy throughout this work. hematologyandoncology.net/archives/july-…
“Revolutionizing Breast Cancer Treatment: The Promise of Antibody-Drug Conjugates” by Samer Alkassis, MD; John A. Glaspy, MD, MPH; and Aditya Bardia, MD, MPH hematologyandoncology.net/archives/july-… @AlkassisSamer @dradityabardia @UCLA #BreastCancer
Kanwarpal S. Kahlon, MD of @UCLAHealthJCCC discusses the availability of the generic formulations of eltrombopag for patients with aplastic anemia and immune thrombocytopenia. Watch the full episode here: hubs.li/Q03xKhL90
A mysterious cellular structure discovered at UCLA decades ago could soon be used to fight cancer. Dr. Leonard Rome’s vault particles are being tested as delivery vehicles for immune-boosting therapies. Learn more: bit.ly/4kG1Ke8

Growing up in Alaska, Dr. David Nathanson (@NathansonLab) dreamed of being a bush pilot. A chance meeting on a fishing trip changed everything and led him to UCLA, where he's now pioneering new therapies for glioblastoma. Read more about his journey: bit.ly/4eQbEbM
The field is booming ! We are Hiring an Associate Director of our Clinical Theranostics Research Program ! Come Working at UCLA to participate in many theranostics clinical trials. recruit.apo.ucla.edu/JPF10478 @UCLA @CzerninJohannes
Redefining academic surgery means moving beyond old practice labels. In @AmJSurgery, UCLA’s Dr. Hines & @DrNimmiKapoor advocate recognizing scholarly contributions of surgeons in all settings and redefining what academic surgery means today. Read more: bit.ly/40RonFh

A new UCLA study may explain why some liver tumors return after heat-based treatment. Researchers found that a protein, Galectin-1, helps cancer cells survive and regrow. Blocking it could make therapy more effective and reduce recurrence. Read more: bit.ly/4lLvQhh
Great work out in @EurUrolOncol led by @JesusJ_MD outstanding PGY-5 @UCLAHealthJCCC . Pooled analysis of two trials of androgen annihilation (ADT+AAP+apa) and RP/RT plus MDT in de novo mHSPC or oligorecurrent mHSPC euoncology.europeanurology.com/article/S2588-…
Researchers at @UCLAHealthJCCC and @dgsomucla are working to launch a first-in-human clinical trial to test the approach. newsroom.ucla.edu/stories/autoim…
By leveraging a unique mechanism of action to target c-MET, telisotuzumab vedotin-tllv represents an additional therapeutic option for patients with c-MET–overexpressing, nonsquamous advanced #NSCLC. @UCLAHealth #LCSM Read more here: hubs.li/Q03wH2nj0
Immunotherapy-Related Diabetes Linked to New Immune Cell Targeted by JAK Inhibitors in Mouse Model @UCLAHealthJCCC is working to launch a first-in-human clinical trial to test the approach in patients with cancer who develop #diabetes after #immunotherapy hubs.li/Q03wt91l0
Congratulations to @ArjanGower on receiving a @NCCN grant to lead a multi-institutional clinical trial testing zipalertinib, a promising targeted therapy for early-stage non-small cell lung cancer with rare EGFR mutations. Read more about the award: bit.ly/407X89l
A new UCLA-led study published in @JCI_insight found that a common autoimmune drug may help reverse immunotherapy-induced diabetes, a rare but life-threatening side effect of cancer treatment. Read more about the findings: bit.ly/3Tv8qRd
“This study offers some of the strongest evidence yet that active surveillance, when guided by modern imaging and minimally invasive treatments like focal therapy, can safely be expanded to more patients.”@UCLAHealthJCCC uclahealth.org/news/release/a…
ICYMI: @DrKEMcCann of @UCLAHealth discusses the need to reach consensus on the potential role of vepdegestrant for ER+/HER2-negative advanced breast cancer at OncLive's #BridgingtheGaps in Breast Cancer meeting. Watch the full clip here📺: onclive.com/view/dr-mccann…